Literature DB >> 12600435

The survival effect of prolactin on PC3 prostate cancer cells.

Alain Ruffion1, Kaltoom A Al-Sakkaf, Barry L Brown, Colby L Eaton, Freddie C Hamdy, Pauline R M Dobson.   

Abstract

OBJECTIVES: Recent studies suggest a paracrine/autocrine loop involving prolactin (PRL) within the human prostate. The aims of this study were to determine the effects of PRL on the growth and survival of prostate cancer cells and the intracellular signalling mechanisms underlying such effects.
METHODS: The effect of PRL on proliferation of LNCaP, PC3 and DU145 was assessed by Coulter counting. The effect of PRL on TRAIL-, staurosporine- and flavopiridol-induced apoptosis was assessed by Timelapse microscopy and Annexin V binding. The status of the PRL receptor (PRL-R) and Akt/PKB (protein kinase B) activity were assessed by Western blotting.
RESULTS: All three cell lines expressed both the short and long forms of the PRL receptor. Although, no significant effect of PRL on the proliferation of these cells was found, PRL partially inhibited TRAIL-induced apoptosis in PC3 cells. PRL also enhanced the phosphorylation of Akt/PKB in these cells.
CONCLUSIONS: PRL had no significant effect on the proliferation of PC3, DU145 and LNCaP, but inhibited TRAIL-induced apoptosis in PC3 cells, possibly via enhanced Akt/PKB phosphorylation in PC3 cells. Further investigations are underway to determine the survival effect of PRL on the other two prostate cancer cell line. Copyright 2003 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12600435     DOI: 10.1016/s0302-2838(03)00038-1

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  12 in total

1.  Does prolactin induce apoptosis? Evidences in a prostate cancer in vitro model.

Authors:  D Giuffrida; A Perdichizzi; M C Giuffrida; S La Vignera; R D'Agata; E Vicari; A E Calogero
Journal:  J Endocrinol Invest       Date:  2009-12-04       Impact factor: 4.256

2.  Prolactin stimulates cell proliferation through a long form of prolactin receptor and K+ channel activation.

Authors:  Fabien Van Coppenolle; Roman Skryma; Halima Ouadid-Ahidouch; Christian Slomianny; Morad Roudbaraki; Philippe Delcourt; Etienne Dewailly; Sandrine Humez; Alexandre Crépin; Isabelle Gourdou; Jean Djiane; Jean-Louis Bonnal; Brigitte Mauroy; Natalia Prevarskaya
Journal:  Biochem J       Date:  2004-02-01       Impact factor: 3.857

3.  Changes in proteomic profiles in different prostate lobes of male rats throughout growth and development and aging stages of the life span.

Authors:  Arunangshu Das; James D Bortner; Cesar A Aliaga; Aaron Baker; Anne Stanley; Bruce A Stanley; Matthew Kaag; John P Richie; Karam El-Bayoumy
Journal:  Prostate       Date:  2012-08-21       Impact factor: 4.104

4.  Differential proteomics in the aging Noble rat ventral prostate.

Authors:  Ying Wai Lam; Neville N C Tam; James E Evans; Karin M Green; Xiang Zhang; Shuk-Mei Ho
Journal:  Proteomics       Date:  2008-07       Impact factor: 3.984

5.  Prolactin signaling enhances colon cancer stemness by modulating Notch signaling in a Jak2-STAT3/ERK manner.

Authors:  Naveen K Neradugomma; Dharmalingam Subramaniam; Ossama W Tawfik; Vincent Goffin; T Rajendra Kumar; Roy A Jensen; Shrikant Anant
Journal:  Carcinogenesis       Date:  2013-11-21       Impact factor: 4.944

6.  Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer.

Authors:  Jongyun Hwang; Sunghun Na; Hyangah Lee; Dongheon Lee
Journal:  J Gynecol Oncol       Date:  2009-09-30       Impact factor: 4.401

Review 7.  What can we learn from rodents about prolactin in humans?

Authors:  Nira Ben-Jonathan; Christopher R LaPensee; Elizabeth W LaPensee
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

8.  Osteoprotegerin and breast cancer risk by hormone receptor subtype: a nested case-control study in the EPIC cohort.

Authors:  Renée T Fortner; Danja Sarink; Helena Schock; Theron Johnson; Anne Tjønneland; Anja Olsen; Kim Overvad; Aurélie Affret; Mathilde His; Marie-Christine Boutron-Ruault; Heiner Boeing; Antonia Trichopoulou; Androniki Naska; Philippos Orfanos; Domenico Palli; Sabina Sieri; Amalia Mattiello; Rosario Tumino; Fulvio Ricceri; H Bas Bueno-de-Mesquita; Petra H M Peeters; Carla H Van Gils; Elisabete Weiderpass; Eiliv Lund; J Ramón Quirós; Antonio Agudo; Maria-José Sánchez; María-Dolores Chirlaque; Eva Ardanaz; Miren Dorronsoro; Tim Key; Kay-Tee Khaw; Sabina Rinaldi; Laure Dossus; Marc Gunter; Melissa A Merritt; Elio Riboli; Rudolf Kaaks
Journal:  BMC Med       Date:  2017-02-08       Impact factor: 8.775

9.  Prolactin receptor antagonism reduces the clonogenic capacity of breast cancer cells and potentiates doxorubicin and paclitaxel cytotoxicity.

Authors:  Sacha J Howell; Elizabeth Anderson; Tom Hunter; Gillian Farnie; Robert B Clarke
Journal:  Breast Cancer Res       Date:  2008-08-05       Impact factor: 6.466

10.  Prolactin acts as a potent survival factor for human breast cancer cell lines.

Authors:  C M Perks; A J Keith; K L Goodhew; P B Savage; Z E Winters; J M P Holly
Journal:  Br J Cancer       Date:  2004-07-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.